Cytokines in clinical cancer treatment trials : methodological aspectsBRENNSCHEIDT, U; LINDEMANN, A.European journal of cancer. Part A. 1994, Vol 30, Num 3, pp 412-414Article

Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2ENGELHARDT, M; WIRTH, K; MERTELSMANN, R et al.European journal of cancer (1990). 1997, Vol 33, Num 7, pp 1050-1054, issn 0959-8049Article

Palmar fibromatosis (Dupuytren's contracture): ultrastructural and enzyme histochemical studies of 43 casesIWASAKI, H; MULLER, H; STUTTE, H. J et al.Virchows Archiv. A, Pathological anatomy and histology. 1984, Vol 405, Num 1, pp 41-53, issn 0340-1227Article

Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9BRENNSCHEIDT, U; RIEDEL, D; KÖLCH, W et al.Cell growth and differentiation. 1994, Vol 5, Num 4, pp 367-372, issn 1044-9523Article

The complete sequence and promoter activity of the human A-raf-1 gene (ARAF1)JONG-EUN LEE; BECK, T. W; BRENNSCHEIDT, U et al.Genomics (San Diego, Calif.). 1994, Vol 20, Num 1, pp 43-55, issn 0888-7543Article

Processing of tumor tissues for vaccination with autologous tumor cellsLAHN, M; KÖHLER, G; ROSENTHAL, F. M et al.European surgical research. 1997, Vol 29, Num 4, pp 292-302, issn 0014-312XArticle

Molecular organization of the human Raf-1 promoter regionBECK, T. W; BRENNSCHEIDT, U; SITHANANDAM, G et al.Molecular and cellular biology (Print). 1990, Vol 10, Num 7, pp 3325-3333, issn 0270-7306, 9 p.Article

γ-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factorRIEDEL, D; LINDEMANN, A; OTTO, J et al.Leukemia. 1990, Vol 4, Num 11, pp 786-789, issn 0887-6924, 4 p.Article

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patientsVAN CUTSEM, E; VERSLYPE, C; BEALE, P et al.Annals of oncology. 2008, Vol 19, Num 2, pp 332-339, issn 0923-7534, 8 p.Article

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patientsGLAUSER, M. P; BRENNSCHEIDT, U; CORNELY, O et al.Clinical microbiology and infection. 2002, Vol 8, Num 1, pp 14-25, issn 1198-743XArticle

Pharmacokinetics of tilidine in terminal renal failureSEILER, K.-U; JÄHNCHEN, E; TRENK, D et al.Journal of clinical pharmacology. 2001, Vol 41, Num 1, pp 79-84, issn 0091-2700Article

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblastsMACKENSEN, A; VEELKEN, H; MERTELSMANN, R et al.Journal of molecular medicine (Berlin. Print). 1997, Vol 75, Num 4, pp 290-296, issn 0946-2716Article

Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumorsMERTELSMANN, R; LINDEMANN, A; BOEHM, T et al.Journal of molecular medicine (Berlin. Print). 1995, Vol 73, Num 4, pp 205-206, issn 0946-2716Conference Paper

Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemiaBRENNSCHEIDT, U; EICK, D; KUNZMANN, R et al.Leukemia. 1994, Vol 8, Num 5, pp 897-902, issn 0887-6924Article